Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals
Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.
QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?
QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.
Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy
Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical […]